Gilead Sciences (NASDAQ:GILD) Price Target Raised to $123.00 at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Gilead to $123 from $118 while maintaining a "sector perform" rating, which implies roughly an 11.26% downside from the current share price.
• Other analysts are more bullish: Gilead has a consensus rating of "Moderate Buy" with a consensus target of $157.81, and multiple firms have lifted targets (e.g., Mizuho $170, Daiwa $161, Truist $152).
• Fundamentals show a recent beat and guidance: Gilead reported Q results of $1.86 EPS (vs. $1.83 est.) and $7.93B revenue (vs. $7.68B), and set FY2026 guidance of $8.45–$8.85 EPS while shares trade around $138.61.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its target price upped by analysts at Royal Bank Of Canada from $118.00 to $123.00 in a research note issued to investors on Tuesday,MarketScreener reports. The firm currently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price target points to a potential downside of 11.26% from the company's current price.

Other equities analysts have also issued research reports about the stock. Citigroup reiterated a "buy" rating on shares of Gilead Sciences in a research report on Friday, March 6th. Mizuho raised their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a research note on Wednesday, February 18th. Wall Street Zen raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 14th. Truist Financial raised their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. Finally, Daiwa Securities Group lifted their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $157.81.

Gilead Sciences Stock Down 1.1%

Shares of NASDAQ GILD opened at $138.61 on Tuesday. The company has a market capitalization of $172.04 billion, a P/E ratio of 20.46, a price-to-earnings-growth ratio of 1.83 and a beta of 0.39. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company's 50 day moving average price is $145.14 and its 200-day moving average price is $129.84.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 EPS. The business's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the insider directly owned 131,779 shares of the company's stock, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 299,280 shares of company stock worth $42,820,550 over the last 90 days. 0.27% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

A number of institutional investors have recently bought and sold shares of GILD. Vanguard Group Inc. increased its stake in Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. State Street Corp raised its holdings in Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock worth $3,399,734,000 after purchasing an additional 1,195,269 shares in the last quarter. Bank of America Corp DE raised its holdings in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock worth $2,837,948,000 after purchasing an additional 3,046,688 shares in the last quarter. Finally, Norges Bank bought a new position in Gilead Sciences in the fourth quarter worth about $2,617,152,000. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.